Skip to main content
Arthritis Research & Therapy logoLink to Arthritis Research & Therapy
. 2018 Dec 7;20:271. doi: 10.1186/s13075-018-1781-y

Correction to: Incidence of giant cell arteritis in Western Norway 1972-2012: a retrospective cohort study

L K Brekke 1,2,3,6,, A P Diamantopoulos 4, B-T Fevang 2,3, J Aβmus 5, E Esperø 1, C G Gjesdal 2,3
PMCID: PMC6284282  PMID: 30526639

Correction to: Arthritis Res Ther (2017) 19:278

https://doi.org/10.1186/s13075-017-1479-6

Following publication of the original article [1], the authors reported an error. The incorrect sex-specific incidences of GCA were published. The correct mean annual cumulative incidence was 22.0 (95% CI 20.6–23.5) for women and 10.5 (95% CI 9.5–11.5) for men; p-value < 0.001 unaffected by the error. Revised versions of Fig. 2 and Table 2 are provided in this correction. Additionally, in the results section (page 4, first section) we report results of a sub-analysis of an extended cohort (n = 881). The correct annual cumulative incidence for women in this group was 24.1 and for men 11.6.

Fig. 2.

Fig. 2

Annual cumulative incidence of giant cell arteritis (American College of Rheumatology (ACR) criteria fulfilled) in Bergen health area 1972–2012. Overall and ESR-specific cumulative incidence calculated as cases per 100,000 general population over the age of 50 years. Incidence by sex was calculated per 100,000 women or men, respectively, and incidence by the different age categories was calculated per 100,000 population of the same age categories (< 60 years, 60–69 years, 70–79 years and 80+ years). Points plotted represent raw incidence. Solid lines were estimated using the smoothing technique of a moving average of 5 years. ESR, erythrocyte sedimentation rate

Table 2.

The incidence of giant cell arteritis (GCA) in Bergen health area 1972–2012

a Mean annual cumulative incidence
All time 1972–1992 1993–2012
Cumulative incidence 95% CI Cumulative incidence 95% CI Cumulative incidence 95% CI
All patients 16.7 (15.5, 18.0) 11.2 (9.8, 12.7) 22.5 (20.5, 24.7)
Sex
 Female 22.0 (20.6, 23.5) 13.3 (11.8, 14.9) 31.2 (28.8, 33.7)
 Male 10.5 (9.5, 11.5) 8.6 (7.4, 9.9) 12.4 (10.9, 14.0)
Age, years
  < 60 2.8 (2.3, 3.3) 1.5 (1.0, 2.1) 4.1 (3.3, 5.0)
 60–69 15.5 (14.4, 16.8) 10.9 (9.6, 12.4) 20.3 (18.4, 22.4)
 70–79 34.5 (32.8, 36.4) 23.4 (21.4, 25.6) 46.2 (43.3, 49.2)
 80+ 26.8 (25.3, 28.4) 14.3 (12.8, 16.0) 39.9 (37.2, 42.7)
ESR, mm/hr
 ESR < 85 8.2 (7.3, 9.1) 4.5 (3.7, 5.5) 12.0 (10.6, 13.6)
 ESR > 85 8.4 (7.6, 9.3) 6.6 (5.5, 7.7) 10.4 (9.0, 11.8)
b Relative risk (RR) according to time, sex, age and ESR
1972–1992 1993–2012
RR 95% CI p-value RR 95% CI p-value
Unadjusted
 Time (years) 1.1 (1.1, 1.1) < 0.001 1.0 (1.0, 1.0) 0.543
Sex
 Time (years) 1.1 (1.1, 1.1) < 0.001 1.0 (1.0, 1.0) 0.462
 Sex (Male vs. Female) 0.6 (0.5, 0.8) < 0.001 0.4 (0.3, 0.5) < 0.001
Age
 Time (years) 1.1 (1.1, 1.1) < 0.001 1.0 (1.0, 1.0) 0.135
 60–69 vs. < 60 7.2 (5.1, 10.6) < 0.001 5.0 (3.9, 6.4) < 0.001
 70–79 vs. < 60 15.4 (11.0, 22.5) < 0.001 11.3 (9.1, 14.3) < 0.001
 80+ vs. < 60 9.5 (6.7, 13.9) < 0.001 9.8 (7.8, 12.4) < 0.001
ESR
 Time (years) 1.1 (1.1, 1.1) < 0.001 1.0 (1.0, 1.0) 0.632
 ESR (>median vs. <median) 1.4 (1.1, 1.9) 0.006 0.9 (0.7, 1.0) 0.116

Overall and ESR-specific cumulative incidence reported as cases per 100,000 background population over the age of 50 years. Incidence for sex reported per 100,000 women or men respectively, and incidence for the different age categories reported per 100,000 population of the same age categories (< 60 years, 60–69 years, 70–79 years and 80+ years). Relative risk calculated according to Poisson regression models for the two timeperiods 1972–1992 and 1993–2012

ESR Erythrocyte sedimentation rate

CI Confidence interval

Reference

  • 1.Brekke LK, et al. Incidence of giant cell arteritis in Western Norway 1972–2012: a retrospective cohort study. Arthritis Res Ther. 2017;19:278. doi: 10.1186/s13075-017-1479-6. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Arthritis Research & Therapy are provided here courtesy of BMC

RESOURCES